An Open-Label, Randomized Trial of Methylphenidate and Atomoxetine Treatment in Adults With ADHD

Objective: To directly compare the efficacy of methylphenidate and atomoxetine in improving symptoms, social functions, and quality of life among adults with ADHD. Method: This was an 8-to-10-week, open-label, head-to-head, randomized clinical trial with two treatment arms: immediate-release methylp...

Full description

Saved in:
Bibliographic Details
Published in:Journal of attention disorders 2017-01, Vol.21 (1), p.27-39
Main Authors: Ni, Hsing-Chang, Lin, Yu-Ju, Gau, Susan Shur-Fen, Huang, Hui-Chun, Yang, Li-Kuang
Format: Article
Language:English
Subjects:
Adolescent
Adult
Atomoxetine Hydrochloride - administration & dosage
Atomoxetine Hydrochloride - adverse effects
Attention Deficit Disorder with Hyperactivity - drug therapy
Central Nervous System Stimulants - administration & dosage
Central Nervous System Stimulants - adverse effects
Drug Administration Schedule
Drug Therapy, Combination
Female
Humans
Male
Medication Adherence
Methylphenidate - administration & dosage
Methylphenidate - adverse effects
Middle Aged
Psychiatric Status Rating Scales
Quality of Life
Treatment Outcome
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objective: To directly compare the efficacy of methylphenidate and atomoxetine in improving symptoms, social functions, and quality of life among adults with ADHD. Method: This was an 8-to-10-week, open-label, head-to-head, randomized clinical trial with two treatment arms: immediate-release methylphenidate (IR-methylphenidate; n = 31) and atomoxetine once daily (n = 32). The outcome measures included ADHD symptom severity, quality of life, and functional impairments. Results: We found a significant reduction in overall ADHD symptoms and improvement in social functions and quality of life for both groups at Weeks 4 to 5 and Weeks 8 to 10. There was no significant difference in the slope of improvements over time except that atomoxetine was superior to IR-methylphenidate in reducing hyperactive/impulsive symptoms at Weeks 4 to 5. There was no significant group difference in the rates of adverse effects. Conclusion: Both IR-methylphenidate and atomoxetine are well tolerated and efficacious in ethnic Chinese adults with ADHD.
ISSN:1087-0547
1557-1246
DOI:10.1177/1087054713476549